School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, Taichung, Taiwan.
Medicine (Baltimore). 2023 Jun 9;102(23):e33907. doi: 10.1097/MD.0000000000033907.
The objective was to assess the role of the combination approach with ezetimibe 10 mg/simvastatin 20 mg versus atorvastatin 40 mg in predicting atrial fibrillation (AF) in type 2 diabetes mellitus patients with acute coronary syndrome and acute ischemic stroke. The authors formed a cohort of diabetic patients with extensive vascular diseases between 2000 and 2018 using data from the National Health Insurance Research Database in Taiwan. AF was the outcome of interest in this study. Cox proportional hazards regression analysis was performed to estimate the hazard ratios and 95% confidence intervals in the analysis. After controlling for sex, age, comorbidities and medications, the patients coexisting with type 2 diabetes mellitus, acute coronary syndrome and acute ischemic stroke with ezetimibe 10 mg/simvastatin 20 mg treatment were not significantly at risk of AF, compared to the patients with atorvastatin 40 mg treatment (adjusted hazard ratio, 0.85; 95% confidence interval, 0.52-1.38). A similar effect for AF risk between ezetimibe 10 mg/simvastatin 20 mg and atorvastatin 40 mg users was observed in the current investigation.
目的在于评估依折麦布 10mg/辛伐他汀 20mg 联合用药方案与阿托伐他汀 40mg 相比，在预测伴有急性冠状动脉综合征和急性缺血性脑卒中的 2 型糖尿病患者心房颤动（AF）方面的作用。作者利用来自台湾全民健康保险研究数据库的数据，于 2000 年至 2018 年间组建了一个包含广泛血管疾病的糖尿病患者队列。本研究中，AF 是感兴趣的结局。采用 Cox 比例风险回归分析来估计分析中的风险比和 95%置信区间。在控制了性别、年龄、合并症和药物后，与接受阿托伐他汀 40mg 治疗的患者相比，同时患有 2 型糖尿病、急性冠状动脉综合征和急性缺血性脑卒中并接受依折麦布 10mg/辛伐他汀 20mg 治疗的患者发生 AF 的风险并无显著升高（校正风险比，0.85；95%置信区间，0.52-1.38）。在当前的研究中，还观察到依折麦布 10mg/辛伐他汀 20mg 与阿托伐他汀 40mg 使用者的 AF 风险之间存在类似的效应。
